Dual‐target inhibitors of bromodomain and extra‐terminal proteins in cancer: A review from medicinal chemistry perspectives
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dual‐target inhibitors of bromodomain and extra‐terminal proteins in cancer: A review from medicinal chemistry perspectives
Authors
Keywords
-
Journal
MEDICINAL RESEARCH REVIEWS
Volume 42, Issue 2, Pages 710-743
Publisher
Wiley
Online
2021-10-14
DOI
10.1002/med.21859
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development
- (2021) Pan Tang et al. JOURNAL OF MEDICINAL CHEMISTRY
- The combined effect of epigenetic inhibitors for LSD1 and BRD4 alters prostate cancer growth and invasion
- (2020) Jianlin Wang et al. Aging-US
- Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer
- (2020) Shipeng He et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Dual-target kinase drug design: Current strategies and future directions in cancer therapy
- (2020) Dejuan Sun et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer
- (2020) Emily J. Faivre et al. NATURE
- Make your best BET: The emerging role of BET inhibitor treatment in malignant tumors
- (2020) Oliver Bechter et al. PHARMACOLOGY & THERAPEUTICS
- The novel dual BET/HDAC inhibitor TW09 mediates cell death by mitochondrial apoptosis in rhabdomyosarcoma cells
- (2020) Stephanie Laszig et al. CANCER LETTERS
- Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors
- (2020) Ning-Yu Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Thieno[2,3-d]pyrimidine-Based Hydroxamic Acid Derivatives as Bromodomain-Containing Protein 4/Histone Deacetylase Dual Inhibitors Induce Autophagic Cell Death in Colorectal Carcinoma Cells
- (2020) Zhaoping Pan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy
- (2020) Tingting Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Achiral Derivatives of Hydroxamate AR-42 Potently Inhibit Class I HDAC Enzymes and Cancer Cell Proliferation
- (2020) Jiahui Tng et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of N-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain
- (2020) George S. Sheppard et al. JOURNAL OF MEDICINAL CHEMISTRY
- Combined targeting of the BRD4-NUT-p300 axis in NUT midline carcinoma by dual selective bromodomain inhibitor, NEO2734
- (2020) Chevaun D Morrison-Smith et al. MOLECULAR CANCER THERAPEUTICS
- Opposing Functions of BRD4 Isoforms in Breast Cancer
- (2020) Shwu-Yuan Wu et al. MOLECULAR CELL
- Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer
- (2020) Shaokun Shu et al. MOLECULAR CELL
- Selective targeting of BD1 and BD2 of the BET proteins in cancer and immuno-inflammation
- (2020) Omer Gilan et al. SCIENCE
- MUC15 inhibits cancer metastasis via PI3K/AKT signaling in renal cell carcinoma
- (2020) Yangyang Yue et al. Cell Death & Disease
- Evolutionary conserved NSL complex/BRD4 axis controls transcription activation via histone acetylation
- (2020) Aline Gaub et al. Nature Communications
- Targeting Super‐Enhancers via Nanoparticle‐Facilitated BRD4 and CDK7 Inhibitors Synergistically Suppresses Pancreatic Ductal Adenocarcinoma
- (2020) Chen‐Song Huang et al. Advanced Science
- Characterization of a dual BET / HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma
- (2020) Xin Zhang et al. INTERNATIONAL JOURNAL OF CANCER
- Rational Design and Evaluation of 6-(Pyrimidin-2-ylamino)-3,4-dihydroquinoxalin-2(1H)-ones as Polypharmacological Inhibitors of BET and Kinases
- (2020) Kaikai Lv et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy
- (2020) Xiaosa Chang et al. Acta Pharmaceutica Sinica B
- Targeting both BET and CBP/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti‐tumor activity in multiple myeloma
- (2020) Katie R. Ryan et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes
- (2020) Jingjing Chen et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseases
- (2020) Ewelina Kulikowski et al. MEDICINAL RESEARCH REVIEWS
- Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734
- (2020) Filippo Spriano et al. Blood Advances
- 4-Acyl Pyrroles as Dual BET-BRD7/9 Bromodomain Inhibitors Address BETi Insensitive Human Cancer Cell Lines
- (2020) Martin Hügle et al. JOURNAL OF MEDICINAL CHEMISTRY
- Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity
- (2019) Ellen Watts et al. JOURNAL OF MEDICINAL CHEMISTRY
- BRD4 directs hematopoietic stem cell development and modulates macrophage inflammatory responses
- (2019) Anup Dey et al. EMBO JOURNAL
- SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer
- (2019) Shweta Joshi et al. MOLECULAR CANCER THERAPEUTICS
- Dynamic Chromatin Targeting of BRD4 Stimulates Cardiac Fibroblast Activation
- (2019) Matthew S. Stratton et al. CIRCULATION RESEARCH
- The novel BET‐CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild‐type prostate cancer
- (2019) Yuqian Yan et al. EMBO Molecular Medicine
- Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK)
- (2019) Xiaotian Kong et al. JOURNAL OF MEDICINAL CHEMISTRY
- Dual Inhibition of TAF1 and BET Bromodomains from the BI-2536 Kinase Inhibitor Scaffold
- (2019) David Remillard et al. ACS Medicinal Chemistry Letters
- Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells
- (2019) Xupeng Mu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Validation of the epigenetic reader bromodomain-containing protein 4 (BRD4) as a therapeutic target for treatment of airway remodeling
- (2019) Allan R. Brasier et al. DRUG DISCOVERY TODAY
- Systematic bromodomain protein screens identify homologous recombination and R-loop suppression pathways involved in genome integrity
- (2019) Jae Jin Kim et al. GENES & DEVELOPMENT
- Small-Molecule Dual PLK1 and BRD4 Inhibitors are Active Against Preclinical Models of Pediatric Solid Tumors
- (2019) Natalie Timme et al. Translational Oncology
- BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency
- (2018) Chaoyang Sun et al. CANCER CELL
- Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2
- (2018) Tomoko Takimoto-Shimomura et al. INVESTIGATIONAL NEW DRUGS
- Structure-Based Discovery and Optimization of Benzo[d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC)
- (2018) Maofeng Zhang et al. JOURNAL OF MEDICINAL CHEMISTRY
- The role of ZA channel water-mediated interactions in the design of bromodomain-selective BET inhibitors
- (2018) Nagakumar Bharatham et al. JOURNAL OF MOLECULAR GRAPHICS & MODELLING
- Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
- (2018) Alan Ashworth et al. Nature Reviews Clinical Oncology
- BRD4 regulates cellular senescence in gastric cancer cells via E2F/miR-106b/p21 axis
- (2018) Xingchen Dong et al. Cell Death & Disease
- BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer
- (2018) Xiangyi Li et al. Cell Reports
- Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains
- (2018) Jinhua Wang et al. ACS Chemical Biology
- Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors
- (2018) Shuai Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Molecular Basis for the N-Terminal Bromodomain and Extra Terminal (BET) Family Selectivity of a Dual Kinase-Bromodomain Inhibitor
- (2018) Anand Divakaran et al. JOURNAL OF MEDICINAL CHEMISTRY
- DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4
- (2018) Xin Jin et al. MOLECULAR CELL
- Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma
- (2018) Joshua Felgenhauer et al. NEOPLASIA
- PLK1: a promising and previously unexplored target in double-hit lymphoma
- (2018) Quais N. Hassan et al. JOURNAL OF CLINICAL INVESTIGATION
- BRD4 and Cancer: going beyond transcriptional regulation
- (2018) Benedetta Donati et al. Molecular Cancer
- Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors
- (2018) Charles Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Design, synthesis and biological evaluation of novel indole derivatives as potential HDAC/BRD4 dual inhibitors and anti-leukemia agents
- (2018) Gaoliang Cheng et al. BIOORGANIC CHEMISTRY
- Downregulation of BRD4 inhibits gallbladder cancer proliferation and metastasis and induces apoptosis via PI3K/AKT pathway
- (2017) Jiaqi Hao et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- RNAi prodrugs targeting Plk1 induce specific gene silencing in primary cells from pediatric T-acute lymphoblastic leukemia patients
- (2017) Iryna Kolosenko et al. JOURNAL OF CONTROLLED RELEASE
- Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia
- (2017) S Peirs et al. LEUKEMIA
- Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics
- (2017) Stuart W. Ember et al. MOLECULAR CANCER THERAPEUTICS
- Prostate cancer–associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4
- (2017) Xiangpeng Dai et al. NATURE MEDICINE
- Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT–mTORC1 activation
- (2017) Pingzhao Zhang et al. NATURE MEDICINE
- Dual-activity PI3K–BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis
- (2017) Forest H. Andrews et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- BET bromodomain inhibition suppresses innate inflammatory and profibrotic transcriptional networks in heart failure
- (2017) Qiming Duan et al. Science Translational Medicine
- PLK1, A Potential Target for Cancer Therapy
- (2017) Zhixian Liu et al. Translational Oncology
- Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomas
- (2017) Carlos Murga-Zamalloa et al. Oncotarget
- Structural Mechanism of the Oxygenase JMJD6 Recognition by the Extraterminal (ET) Domain of BRD4
- (2017) Tsuyoshi Konuma et al. Scientific Reports
- Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer
- (2017) Alfonso Urbanucci et al. Cell Reports
- BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1
- (2017) Simon J. Hogg et al. Cell Reports
- The role of the ALK receptor in cancer biology
- (2016) B. Hallberg et al. ANNALS OF ONCOLOGY
- Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors
- (2016) Zhimin Zhang et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Structure–Activity Relationship Study of N6-Benzoyladenine-Type BRD4 Inhibitors and Their Effects on Cell Differentiation and TNF-α Production
- (2016) Seika Amemiya et al. CHEMICAL & PHARMACEUTICAL BULLETIN
- AMPK–ULK1-Mediated Autophagy Confers Resistance to BET Inhibitor JQ1 in Acute Myeloid Leukemia Stem Cells
- (2016) Ji Eun Jang et al. CLINICAL CANCER RESEARCH
- The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects
- (2016) J. Shahbazi et al. CLINICAL CANCER RESEARCH
- Bromodomain inhibitors and cancer therapy: From structures to applications
- (2016) Montserrat Pérez-Salvia et al. Epigenetics
- Dual Kinase-Bromodomain Inhibitors in Anticancer Drug Discovery: A Structural and Pharmacological Perspective
- (2016) Luca Carlino et al. JOURNAL OF MEDICINAL CHEMISTRY
- Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials
- (2016) Brian K. Albrecht et al. JOURNAL OF MEDICINAL CHEMISTRY
- Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma
- (2016) A. R. Singh et al. MOLECULAR CANCER THERAPEUTICS
- Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics
- (2016) Rosie Elizabeth Ann Gutteridge et al. MOLECULAR CANCER THERAPEUTICS
- Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
- (2016) Shaokun Shu et al. NATURE
- Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk
- (2016) Sara Sdelci et al. Nature Chemical Biology
- BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin
- (2016) Ballachanda N Devaiah et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Synthetic lethal approaches for assessing combinatorial efficacy of chemotherapeutic drugs
- (2016) Rebecca A. Jackson et al. PHARMACOLOGY & THERAPEUTICS
- BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin
- (2016) Ballachanda N Devaiah et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression
- (2016) Hengrui Zhu et al. Cell Reports
- Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer
- (2016) Alison M. Kurimchak et al. Cell Reports
- Dual Screening of BPTF and Brd4 Using Protein-Observed Fluorine NMR Uncovers New Bromodomain Probe Molecules
- (2015) Andrew K. Urick et al. ACS Chemical Biology
- Discovery and structure–activity relationship studies of N6-benzoyladenine derivatives as novel BRD4 inhibitors
- (2015) Tomomi Noguchi-Yachide et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Protein Lysine Acetylation by p300/CBP
- (2015) Beverley M. Dancy et al. CHEMICAL REVIEWS
- Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition
- (2015) A. Henssen et al. CLINICAL CANCER RESEARCH
- Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors
- (2015) F. Anthony Romero et al. JOURNAL OF MEDICINAL CHEMISTRY
- Transcriptional plasticity promotes primary and acquired resistance to BET inhibition
- (2015) Philipp Rathert et al. NATURE
- BET inhibitor resistance emerges from leukaemia stem cells
- (2015) Chun Yew Fong et al. NATURE
- BRD4 is a novel therapeutic target for liver fibrosis
- (2015) Ning Ding et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Beating the odds: BETs in disease
- (2015) Chen-Yi Wang et al. TRENDS IN BIOCHEMICAL SCIENCES
- BRD4 Structure–Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536
- (2015) Lijia Chen et al. ACS Medicinal Chemistry Letters
- Large-Scale Computational Screening Identifies First in Class Multitarget Inhibitor of EGFR Kinase and BRD4
- (2015) Bryce K. Allen et al. Scientific Reports
- GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1
- (2015) Krishan Kumar et al. Scientific Reports
- Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors
- (2014) Stuart W. J. Ember et al. ACS Chemical Biology
- An epigenomic approach to therapy for tamoxifen-resistant breast cancer
- (2014) Qin Feng et al. CELL RESEARCH
- Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma
- (2014) Dhong Hyun Lee et al. INTERNATIONAL JOURNAL OF CANCER
- The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition
- (2014) Junwei Shi et al. MOLECULAR CELL
- Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
- (2014) Pietro Ciceri et al. Nature Chemical Biology
- Targeting bromodomains: epigenetic readers of lysine acetylation
- (2014) Panagis Filippakopoulos et al. NATURE REVIEWS DRUG DISCOVERY
- Brd4 activates P-TEFb for RNA polymerase II CTD phosphorylation
- (2014) Friederike Itzen et al. NUCLEIC ACIDS RESEARCH
- BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma
- (2014) Joydeep Bhadury et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The structure based design of dual HDAC/BET inhibitors as novel epigenetic probes
- (2014) Stephen J. Atkinson et al. MedChemComm
- The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response
- (2014) M Hussong et al. Cell Death & Disease
- Inducible In Vivo Silencing of Brd4 Identifies Potential Toxicities of Sustained BET Protein Inhibition
- (2014) Jessica E. Bolden et al. Cell Reports
- Bromodomain Protein BRD4 Is Required for Estrogen Receptor-Dependent Enhancer Activation and Gene Transcription
- (2014) Sankari Nagarajan et al. Cell Reports
- The Commonly Used PI3-Kinase Probe LY294002 Is an Inhibitor of BET Bromodomains
- (2013) Antje Dittmann et al. ACS Chemical Biology
- Cyclin-Dependent Kinase Inhibitor Dinaciclib Interacts with the Acetyl-Lysine Recognition Site of Bromodomains
- (2013) Mathew P. Martin et al. ACS Chemical Biology
- 2-Amino-[1,2,4]triazolo[1,5-a]pyridines as JAK2 inhibitors
- (2013) Michael Siu et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair
- (2013) B Groselj et al. BRITISH JOURNAL OF CANCER
- BRD4 Sustains Melanoma Proliferation and Represents a New Target for Epigenetic Therapy
- (2013) M. F. Segura et al. CANCER RESEARCH
- Recruitment of Brd4 to the Human Papillomavirus Type 16 DNA Replication Complex Is Essential for Replication of Viral DNA
- (2013) X. Wang et al. JOURNAL OF VIROLOGY
- Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia
- (2013) M A Dawson et al. LEUKEMIA
- Phospho Switch Triggers Brd4 Chromatin Binding and Activator Recruitment for Gene-Specific Targeting
- (2013) Shwu-Yuan Wu et al. MOLECULAR CELL
- The bromodomain protein Brd4 insulates chromatin from DNA damage signalling
- (2013) Scott R. Floyd et al. NATURE
- Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA
- (2013) Z Zou et al. ONCOGENE
- BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models
- (2013) Anastasia Wyce et al. PLoS One
- RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain
- (2013) S. Picaud et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition
- (2013) Alexandre Puissant et al. Cancer Discovery
- The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma
- (2012) Teeara Berry et al. CANCER CELL
- Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
- (2012) Panagis Filippakopoulos et al. CELL
- Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies
- (2012) D. Mahadevan et al. EUROPEAN JOURNAL OF CANCER
- Identification of a Chemical Probe for Bromo and Extra C-Terminal Bromodomain Inhibition through Optimization of a Fragment-Derived Hit
- (2012) Paul V. Fish et al. JOURNAL OF MEDICINAL CHEMISTRY
- Epigenetic protein families: a new frontier for drug discovery
- (2012) Cheryl H. Arrowsmith et al. NATURE REVIEWS DRUG DISCOVERY
- BRD4 is an atypical kinase that phosphorylates Serine2 of the RNA Polymerase II carboxy-terminal domain
- (2012) B. N. Devaiah et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Place your BETs: the therapeutic potential of bromodomains
- (2012) R.K. Prinjha et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- 3,5-Dimethylisoxazoles Act As Acetyl-lysine-mimetic Bromodomain Ligands
- (2011) David S. Hewings et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery and Characterization of Small Molecule Inhibitors of the BET Family Bromodomains
- (2011) Chun-wa Chung et al. JOURNAL OF MEDICINAL CHEMISTRY
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
- (2011) Johannes Zuber et al. NATURE
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
- (2011) Mark A. Dawson et al. NATURE
- c-Myc Regulates Transcriptional Pause Release
- (2010) Peter B. Rahl et al. CELL
- Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
- (2010) David Parry et al. MOLECULAR CANCER THERAPEUTICS
- Suppression of inflammation by a synthetic histone mimic
- (2010) Edwige Nicodeme et al. NATURE
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- Structures of the Dual Bromodomains of the P-TEFb-activating Protein Brd4 at Atomic Resolution
- (2009) Friederike Vollmuth et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation
- (2008) Sonja Baumli et al. EMBO JOURNAL
- Discovery of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a Novel and Potent Vascular Endothelial Growth Factor Receptor Inhibitor†
- (2008) Philip A. Harris et al. JOURNAL OF MEDICINAL CHEMISTRY
- Brd4 Coactivates Transcriptional Activation of NF- B via Specific Binding to Acetylated RelA
- (2008) B. Huang et al. MOLECULAR AND CELLULAR BIOLOGY
- Identification of ALK as a major familial neuroblastoma predisposition gene
- (2008) Yaël P. Mossé et al. NATURE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More